STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis | MicrobiomeTrials← Back to trialsNCT05603702
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-03-17Est. Completion: 2027-03-31
Enrollment target: 21 participants Locations- Stanford University, Stanford, California, United States
- Indiana University, Indianapolis, Indiana, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Other microbiome trials you might be interested in
Chronic Venous Insufficiency, CVI
This is a prospective, single-arm, pre-post interventional study designed to evaluate the feasibility, safety, and impac…
Bydgoszcz, PolandCompleted May 10, 2028
Polypathology
For several decades, there is an aging population, particularly in industrialized countries. This lengthening of the dur…
Limoges, FranceCompleted Jan 2018
IsolationAnxietyHealth Care UtilizationSickle Cell DiseasePain
Background:
Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. Peopl…
Bethesda, United StatesCompleted May 18, 2022